… compared roxadustat versus darbepoetin alfa (DA) in non-dialysis-dependent (NDD) CKD
… Roxadustat is a viable option to treat anaemia in NDD CKD patients maintaining Hb levels …

… , placebo-controlled study examined patients with Stages 3–5 CKD, not on dialysis (NCT01887600).
Patients were randomized (2:1) to oral roxadustat or placebo three times weekly for …

… assigned 154 patients with chronic kidney disease in a 2:1 ratio to receive roxadustat or
placebo three times a week for 8 weeks in a double-blind manner. All the patients had a …

… was reduced in dialysis-dependent-CKD patients treated with roxadustat compared with
erythropoiesis-stimulating agents. Thus, the efficacy of roxadustat is without question, and all …

… This narrative review describes the effects of roxadustat on iron parameters … in patients with
anemia of non-dialysis-dependent (NDD) or dialysis-dependent (DD) chronic kidney disease …

… receiving the dialysis was unclear. The aim of this study was to evaluate the efficacy of
roxadustat for the treatment of anemia in patients who are dialysis dependent (DD) or dialysis …

… to those treated with roxadustat (mean dose of 1.3 mg/kg, EPO of ∼130 mIU/ml). … during
roxadustat treatment [Citation42]. Sixty incident dialysis patients were all started to roxadustat …

… –response of roxadustat in Japanese patients with anemia and NDD-CKD. … without rendering
patients functionally or absolutely iron deficient, and 33.8% of patients receiving roxadustat …

… 8-week treatment with doses of roxadustat in the same dose range as those used in this
study in patients who were not previously treated with ESA and not dialysis-dependent resulted …

… ] and whether the patients got dialysis, we performed four subgroup analyses depending
on whether the patient received a high/low dose of roxadustat or whether the patient had NDD/…